RxDoctor Payments Data

Richard Kalman, MD

Gastroenterology · Philadelphia, PANPI 1184891020

Payments from drug & device makers

$71,829in general payments, 2019–2025

Across 48 payments — averaging $1496.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$40K
  • Astrazeneca UK Limited$11K
  • Gilead$11K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Tanabe Pharma America, Inc.$3K
  • Genentech USA, Inc.$2K
  • plus $328 from 6 others

What the payments were for

  • Consulting fees$1,85214%
  • Speaking & faculty fees$10,28079%
  • Food & beverage$7816%
  • Education$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,829 in reported general payments places this provider in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$53,777
Medicare patients
208
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin95$367,653
VemlidyTenofovir Alafenamide101$151,478
OcalivaObeticholic Acid11$93,144
Envarsus XrTacrolimus26$33,925
Tacrolimus194$15,579
Ursodiol132$14,285
Mycophenolate Mofetil139$12,885
Sirolimus18$10,075
Entecavir56$7,186
LokelmaSodium Zirconium Cyclosilicate12$5,942
Cyclosporine ModifiedCyclosporine, Modified33$4,865
Mycophenolic AcidMycophenolate Sodium30$3,594
Azathioprine75$2,277
Lactulose39$1,022
Pantoprazole Sodium97$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$10,777$151,478101 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →